Company profile

Nerviano Medical Sciences (Shanghai) Ltd.

Privately held: no public share price (China subsidiary (est. Aug 2025) of privately held Nerviano Medical Sciences S.r.l.; neither entity is listed. Parent: Nerviano Medical Sciences S.r.l. (Italy, private). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.nervianoms.com/nerviano-medical-sciences-srl-launches-china-subsidiary-to-advance-oncology-pipeline-and-adc-portfolio/]) · China

Assets

(1 total)

1Total Assets

0Approved

0Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 1 of 1 assets

		Target & Modality
atamparib	Phase 2	PARP7 (TIPARP)Small molecule	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.